Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Outcome of early treatment of COVID-19 with antivirals or anti-spike monoclonal antibodies (MABs) in patients with haematological malignancies (HM) is unknown. A retrospective study of HM patients treated for mild/moderate COVID-19 between March 2021 and July 2022 was performed. The main composite end-point was treatment failure (severe COVID-19 or COVID-19-related death). We included 328 consecutive patients who received MABs (n = 120, 37%; sotrovimab, n = 73) or antivirals (n = 208, 63%; nirmatrelvir/ritonavir, n = 116) over a median of two days after symptoms started; 111 (33.8%) had non-Hodgkin lymphoma (NHL); 89 (27%) were transplant/CAR-T (chimaeric antigen receptor T-cell therapy) recipients. Most infections (n = 309, 94%) occurred during the Omicron period. Failure developed in 31 patients (9.5%). Its independent predictors were older age, fewer vaccine doses, and treatment with MABs. Rate of failure was lower in the Omicron versus the pre-Omicron period (7.8% versus 36.8%, p < 0.001). During the Omicron period, predictors of failure were age, fewer vaccine doses and diagnosis of acute myeloid leukaemia/myelodysplastic syndrome (AML/MDS). Independent predictors of longer viral shedding were age, comorbidities, hospital admission at diagnosis, NHL/CLL, treatment with MABs. COVID-19-associated mortality was 3.4% (n = 11). The mortality in those who developed severe COVID-19 after early treatment was 26% in the Omicron period. Patients with HM had a significant risk of failure of early treatment, even during the Omicron period, with high mortality rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:201 |
|---|---|
| Enthalten in: |
British journal of haematology - 201(2023), 4 vom: 01. Mai, Seite 628-639 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mikulska, Malgorzata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-SARS-CoV-2 monoclonal antibodies |
|---|
| Anmerkungen: |
Date Completed 04.05.2023 Date Revised 11.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18690 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35312544X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35312544X | ||
| 003 | DE-627 | ||
| 005 | 20231226055308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18690 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM35312544X | ||
| 035 | |a (NLM)36806152 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mikulska, Malgorzata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2023 | ||
| 500 | |a Date Revised 11.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Outcome of early treatment of COVID-19 with antivirals or anti-spike monoclonal antibodies (MABs) in patients with haematological malignancies (HM) is unknown. A retrospective study of HM patients treated for mild/moderate COVID-19 between March 2021 and July 2022 was performed. The main composite end-point was treatment failure (severe COVID-19 or COVID-19-related death). We included 328 consecutive patients who received MABs (n = 120, 37%; sotrovimab, n = 73) or antivirals (n = 208, 63%; nirmatrelvir/ritonavir, n = 116) over a median of two days after symptoms started; 111 (33.8%) had non-Hodgkin lymphoma (NHL); 89 (27%) were transplant/CAR-T (chimaeric antigen receptor T-cell therapy) recipients. Most infections (n = 309, 94%) occurred during the Omicron period. Failure developed in 31 patients (9.5%). Its independent predictors were older age, fewer vaccine doses, and treatment with MABs. Rate of failure was lower in the Omicron versus the pre-Omicron period (7.8% versus 36.8%, p < 0.001). During the Omicron period, predictors of failure were age, fewer vaccine doses and diagnosis of acute myeloid leukaemia/myelodysplastic syndrome (AML/MDS). Independent predictors of longer viral shedding were age, comorbidities, hospital admission at diagnosis, NHL/CLL, treatment with MABs. COVID-19-associated mortality was 3.4% (n = 11). The mortality in those who developed severe COVID-19 after early treatment was 26% in the Omicron period. Patients with HM had a significant risk of failure of early treatment, even during the Omicron period, with high mortality rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-SARS-CoV-2 monoclonal antibodies | |
| 650 | 4 | |a haematologic malignancy | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a nirmatrelvir | |
| 650 | 4 | |a remdesivir | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Testi, Diletta |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Balletto, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sepulcri, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bussini, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Dentone, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Magne, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Policarpo, Sílvia |e verfasserin |4 aut | |
| 700 | 1 | |a Campoli, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Miselli, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Cilli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiggi, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Aquino, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Di Grazia, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Giannella, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Giacobbe, Daniele Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vena, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Raiola, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifazi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Zinzani, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Angelucci, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoletti, Michele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 201(2023), 4 vom: 01. Mai, Seite 628-639 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:201 |g year:2023 |g number:4 |g day:01 |g month:05 |g pages:628-639 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18690 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 201 |j 2023 |e 4 |b 01 |c 05 |h 628-639 | ||